Name: Cytokinetics Inc. (NASDAQ:CYTK) | Liabilities and Stockholders’ Equity
Creator: Stock Analysis on Net

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Download chart

Cytokinetics Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Accounts payable	25,611)	21,087)	8,050)	8,160)	3,764)
Clinical and preclinical costs	16,105)	13,872)	6,124)	2,215)	8,618)
Compensation related	21,767)	14,930)	11,787)	8,343)	6,118)
Other accrued expenses	6,224)	5,568)	1,404)	1,565)	1,021)
Accrued liabilities	44,096)	34,370)	19,315)	12,123)	15,757)
Current portion of term loan	—)	—)	—)	—)	2,607)
Short-term operating lease liabilities	12,829)	14,863)	2,785)	4,616)	—)
Short-term finance lease liabilities	1,000)	500)	—)	—)	—)
Other current liabilities	1,081)	1,040)	1,049)	1,124)	66)
Current liabilities	84,617)	71,860)	31,199)	26,023)	22,194)
Term loan, net, excluding current portion	63,810)	47,367)	46,209)	45,052)	39,806)
Convertible notes, net	545,808)	95,471)	89,504)	84,205)	—)
Liabilities related to revenue participation right purchase agreements, net	300,501)	179,072)	166,068)	143,276)	122,473)
Long-term deferred revenue	—)	87,000)	87,000)	—)	—)
Long-term operating lease liabilities	126,895)	112,229)	440)	2,195)	—)
Long-term finance lease liabilities	1,001)	805)	—)	—)	—)
Other non-current liabilities	43)	3,652)	—)	—)	771)
Non-current liabilities	1,038,058)	525,596)	389,221)	274,728)	163,050)
Total liabilities	1,122,675)	597,456)	420,420)	300,751)	185,244)
Preferred stock, $0.001 par value; issued and outstanding: none	—)	—)	—)	—)	—)
Common stock, $0.001 par value	94)	84)	70)	59)	55)
Additional paid-in capital	1,481,590)	1,452,268)	1,105,470)	853,341)	768,703)
Accumulated other comprehensive income (loss)	(3,590)	(869)	149)	679)	500)
Accumulated deficit	(1,585,994)	(1,207,620)	(992,306)	(865,016)	(743,324)
Stockholders’ equity (deficit)	(107,900)	243,863)	113,383)	(10,937)	25,934)
Total liabilities and stockholders’ equity (deficit)	1,014,775)	841,319)	533,803)	289,814)	211,178)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

The financial position of the entity reflects a period of aggressive expansion in liabilities and significant volatility in stockholders' equity between 2018 and 2022. Total liabilities increased from 185.2 million US dollars in 2018 to 1.12 billion US dollars in 2022, representing a substantial upward trajectory in the company's leverage.

Debt and Long-Term Obligations: A primary driver of the increase in total liabilities is the sharp rise in non-current liabilities, which grew from 163.1 million US dollars in 2018 to 1.04 billion US dollars in 2022. This growth is most prominent in convertible notes, which were non-existent in 2018 but surged to 545.8 million US dollars by the end of 2022. Additionally, liabilities related to revenue participation right purchase agreements showed a steady increase, rising from 122.5 million US dollars in 2018 to 300.5 million US dollars in 2022. Term loans, net of current portions, also trended upward, ending the period at 63.8 million US dollars.
Current Liability Trends: Current liabilities experienced a consistent increase, moving from 22.2 million US dollars in 2018 to 84.6 million US dollars in 2022. This growth was fueled by a significant rise in accounts payable, which increased from 3.8 million US dollars to 25.6 million US dollars, and accrued liabilities, which grew from 15.8 million US dollars to 44.1 million US dollars. Short-term operating lease liabilities also became a more significant component of the current liability structure starting in 2019, peaking at 14.9 million US dollars in 2021 before slightly declining to 12.8 million US dollars in 2022.
Stockholders' Equity and Deficits: The equity position exhibits extreme volatility. Stockholders' equity fluctuated from a positive 25.9 million US dollars in 2018 to a deficit of 10.9 million US dollars in 2019, recovered to a peak of 243.9 million US dollars in 2021, and ultimately fell to a deficit of 107.9 million US dollars in 2022. This volatility is characterized by a widening accumulated deficit, which grew from 743.3 million US dollars in 2018 to 1.59 billion US dollars in 2022, offset partially by increases in additional paid-in capital, which rose from 768.7 million US dollars to 1.48 billion US dollars over the same period.
Overall Capital Structure Analysis: By the end of 2022, the balance sheet transitioned to a structure heavily dependent on debt, as evidenced by the total liabilities exceeding the total assets implied by the total liabilities and stockholders' equity deficit. The shift from a positive equity position in 2021 to a negative equity position in 2022 indicates that the increase in liabilities and the growth of the accumulated deficit outpaced the capital raised through the issuance of stock.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?